SCHEMBL30045772

SCHEMBL30045772

CC(C)(C)OC(=O)N(c1cscn1)S(=O)(=O)c1ccc(Cl)nc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.42
SCN8A Q9UQD0 1/20 0.42
MAPT P10636 1/20 0.41
ALDH1A1 P00352 6/20 0.40
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
LMNA P02545 1/20 0.34
MAPK1 P28482 1/20 0.34
KDM4E B2RXH2 1/20 0.33
PTPN22 Q9Y2R2 1/20 0.33
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32
SLC16A3 O15427 1/20 0.32
SLC16A1 P53985 1/20 0.32
MCTS1 Q9ULC4 1/20 0.32
EGFR P00533 1/20 0.31
GAA P10253 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21783501 1.00 SMN1; SMN2 (0.42) SMN1; SMN2SCN8AMAPTALDH1A1MEN1
SCHEMBL30047031 0.85 ALDH1A1 (0.43) SCN8AMAPTALDH1A1TDP1L3MBTL1
SCHEMBL21783446 0.85 ALDH1A1 (0.43) SCN8AMAPTALDH1A1TDP1L3MBTL1
SCHEMBL19627627 0.83 SCN8A (0.46) SCN8AMAPTMEN1KMT2A
SCHEMBL21783363 0.83 SCN8A (0.43) SCN8AALDH1A1
SCHEMBL19627632 0.83 SCN8A (0.45) SCN8AMAPTMEN1KMT2ASLC16A3
SCHEMBL21777235 0.83 ALDH1A1 (0.47) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL22473202 0.81 SCN8A (0.40) SCN8ATDP1SLC16A3SLC16A1MCTS1
SCHEMBL30693037 0.80 SMN1; SMN2 (0.51) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL19627733 0.78 SCN8A (0.44) SCN8ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11639351-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. 2023-05-02 US disclosed
US-20220348570-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2022-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11639351-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents SCN1A, SCN2A, SCN2B SMN1; SMN2 323/4885SCN8A 6/4885MAPT 195/4885
US-20220348570-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN2A, SCN2B SMN1; SMN2 323/4885SCN8A 6/4885MAPT 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.